rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

10% owner

Company insider

Files Form 4 as: 10% owner, Braveheart Bio; 10% owner, Kailera Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
12
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
2
Companies where not an officer
2
First trade
20 Apr 2026
Last trade
7 Aug 2026
Last filed
10 Aug 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
BRVE Braveheart Bio10% owner · Biotechnology · last 7 Aug 20260 buys · 0 sells
KLRA Kailera Therapeutics10% owner · Biotechnology · last 20 Apr 20260 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
7 Aug 2026filed 10 Aug 2026BRVE Braveheart BioBiotechnologySEC FORM 4 Code C—7,420,091filing
7 Aug 2026filed 10 Aug 2026BRVE Braveheart Biooption or derivative · BiotechnologySEC FORM 4 Code C—32,500,000 at $0.00filing
7 Aug 2026filed 10 Aug 2026BRVE Braveheart Biooption or derivative · BiotechnologySEC FORM 4 Code C—32,500,000 at $0.00filing
7 Aug 2026filed 10 Aug 2026BRVE Braveheart BioBiotechnologySEC FORM 4 Code C—7,420,091filing
20 Apr 2026filed 22 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Code C—9,477,719filing
20 Apr 2026filed 22 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Code C—2,034,133filing
20 Apr 2026filed 22 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—4,968,789 at $0.00filing
20 Apr 2026filed 22 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—4,968,789 at $0.00filing
20 Apr 2026filed 22 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—708,814 at $0.00filing
20 Apr 2026filed 22 Apr 2026KLRA Kailera Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code C—708,814 at $0.00filing
20 Apr 2026filed 22 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Code C—9,477,719filing
20 Apr 2026filed 22 Apr 2026KLRA Kailera TherapeuticsBiotechnologySEC FORM 4 Code C—2,034,133filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Nur NicholsonChief Technology Officer · Chief Technology Officer at Kailera Therapeutics, filing Form 4 there in the last year
Erez ChimovitsDirector · Director and 10% owner at Braveheart Bio, filing Form 4 there in the last year
ORBIMED ADVISORS LLCDirector and 10% owner · Director and 10% owner at Braveheart Bio, filing Form 4 there in the last year
Marc L. AndreessenDirector · 10% owner at Braveheart Bio, filing Form 4 there in the last year
AH Bio Fund IV, L.P.10% owner · 10% owner at Braveheart Bio, filing Form 4 there in the last year